Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

Evidence-based review and assessment of botulinum neurotoxin for the treatment of urologic conditions.

Chancellor MB, Elovic E, Esquenazi A, Naumann M, Segal KR, Schiavo G, Smith CP, Ward AB.

Toxicon. 2013 Jun 1;67:129-40. doi: 10.1016/j.toxicon.2013.01.020. Epub 2013 Feb 13. Review.

PMID:
23415704
2.

Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.

Hallett M, Albanese A, Dressler D, Segal KR, Simpson DM, Truong D, Jankovic J.

Toxicon. 2013 Jun 1;67:94-114. doi: 10.1016/j.toxicon.2012.12.004. Epub 2013 Feb 4. Review.

PMID:
23380701
3.

Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders.

Naumann M, Dressler D, Hallett M, Jankovic J, Schiavo G, Segal KR, Truong D.

Toxicon. 2013 Jun 1;67:141-52. doi: 10.1016/j.toxicon.2012.10.020. Epub 2012 Nov 23. Review.

PMID:
23178324
4.

Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome.

Esquenazi A, Albanese A, Chancellor MB, Elovic E, Segal KR, Simpson DM, Smith CP, Ward AB.

Toxicon. 2013 Jun 1;67:115-28. doi: 10.1016/j.toxicon.2012.11.025. Epub 2012 Dec 5. Review.

PMID:
23220492
5.

Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Naumann M, So Y, Argoff CE, Childers MK, Dykstra DD, Gronseth GS, Jabbari B, Kaufmann HC, Schurch B, Silberstein SD, Simpson DM; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Neurology. 2008 May 6;70(19):1707-14. doi: 10.1212/01.wnl.0000311390.87642.d8.

PMID:
18458231
6.

More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.

Leitner L, Guggenbühl-Roy S, Knüpfer SC, Walter M, Schneider MP, Tornic J, Sammer U, Mehnert U, Kessler TM.

Eur Urol. 2016 Sep;70(3):522-8. doi: 10.1016/j.eururo.2016.03.052. Epub 2016 Apr 19.

PMID:
27106070
7.

Botulinum toxin in urology: a review of clinical potential in the treatment of urologic and sexual conditions.

Chung E.

Expert Opin Biol Ther. 2015 Jan;15(1):95-102. doi: 10.1517/14712598.2015.974543. Epub 2014 Oct 27. Review.

PMID:
25347039
8.
9.

Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA).

Mangera A, Andersson KE, Apostolidis A, Chapple C, Dasgupta P, Giannantoni A, Gravas S, Madersbacher S.

Eur Urol. 2011 Oct;60(4):784-95. doi: 10.1016/j.eururo.2011.07.001. Epub 2011 Jul 13. Review.

PMID:
21782318
10.

Use of Botulinum Toxin A in the Treatment of Lower Urinary Tract Disorders: A Review of the Literature.

Moore DC, Cohn JA, Dmochowski RR.

Toxins (Basel). 2016 Mar 23;8(4):88. doi: 10.3390/toxins8040088. Review.

11.

Clinical differences between botulinum neurotoxin type A and B.

Bentivoglio AR, Del Grande A, Petracca M, Ialongo T, Ricciardi L.

Toxicon. 2015 Dec 1;107(Pt A):77-84. doi: 10.1016/j.toxicon.2015.08.001. Epub 2015 Aug 7. Review.

PMID:
26260691
12.

Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primer.

Chen JJ, Dashtipour K.

Pharmacotherapy. 2013 Mar;33(3):304-18. doi: 10.1002/phar.1196. Epub 2013 Feb 11. Review.

PMID:
23400888
13.

Hyperhidrosis: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins.

Lakraj AA, Moghimi N, Jabbari B.

Toxins (Basel). 2013 Apr 23;5(4):821-40. doi: 10.3390/toxins5040821. Review.

14.

An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders.

Mangera A, Apostolidis A, Andersson KE, Dasgupta P, Giannantoni A, Roehrborn C, Novara G, Chapple C.

Eur Urol. 2014 May;65(5):981-90. doi: 10.1016/j.eururo.2013.10.033. Epub 2013 Nov 1. Review.

PMID:
24239446
15.

Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review.

Linsenmeyer TA.

J Spinal Cord Med. 2013 Sep;36(5):402-19. doi: 10.1179/2045772313Y.0000000116. Review.

16.

Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury.

Mehta S, Hill D, McIntyre A, Foley N, Hsieh J, Ethans K, Teasell RW, Loh E, Welk B, Wolfe D.

Arch Phys Med Rehabil. 2013 Aug;94(8):1473-81. doi: 10.1016/j.apmr.2013.04.011. Epub 2013 Apr 28. Review.

PMID:
23632286
17.

Botulinum toxin-what urologic uses does the data support?

Seth J, Khan MS, Dasgupta P, Sahai A.

Curr Urol Rep. 2013 Jun;14(3):227-34. doi: 10.1007/s11934-013-0326-9. Review.

PMID:
23625366
18.

Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).

Cruz F, Nitti V.

Neurourol Urodyn. 2014 Jul;33 Suppl 3:S26-31. doi: 10.1002/nau.22630. Review.

PMID:
25042140
19.

Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.

Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, Daniell G, Heesakkers J, Haag-Molkenteller C.

Eur Urol. 2011 Oct;60(4):742-50. doi: 10.1016/j.eururo.2011.07.002. Epub 2011 Jul 13.

PMID:
21798658
20.

Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report.

Apostolidis A, Dasgupta P, Denys P, Elneil S, Fowler CJ, Giannantoni A, Karsenty G, Schulte-Baukloh H, Schurch B, Wyndaele JJ; European Consensus Panel.

Eur Urol. 2009 Jan;55(1):100-19. doi: 10.1016/j.eururo.2008.09.009. Epub 2008 Sep 17. Review.

PMID:
18823697

Supplemental Content

Support Center